Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Jacobino, S.R.; Nederend, M.; Reijneveld, J.F.; Augustijn, D.; Jansen, J.H.M.; Meeldijk, J.; ... ; Leusen, J.H.W. (2018)

Article / Letter to editor

• antibody glycosylation
• dIgA
• Fc receptor
• fusion protein
• IgG
• mIgA
• motavizumab
• neutralizing antibodies
• palivizumab
• RSV
• sIgA

• All authors: Jacobino, S.R.; Nederend, M.; Reijneveld, J.F.; Augustijn, D.; Jansen, J.H.M.; Meeldijk, J.; Reiding, K.R.; Wuhrer, M.; Coenjaerts, F.E.J.; Hack, C.E.; Bont, L.J.; Leusen, J.H.W.
• Date: 2018-12-31
• Journal: mAbs
• Volume: 10
• Issue: 3
• Pages: 453 - 462
• DOI: doi:10.1080/19420862.2018.1433974
• Link: https://www.tandfonline.com/doi/full/10.1080/19420862.2018.1433974